Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in KínaPhase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 230
- Run by
- Zhejiang Haichang Biotech Co., Ltd.
See details and how to joinNCT07494435 - 1/2. fázisTaking peopleA Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Yinghua Xu
See details and how to joinNCT07495215 - 1/2. fázisTaking peoplePhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Where
- Beijing, Bengbu, Changchun, Dalian, Dongguan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Jinan, Kunming, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Ürümqi, Xiamen, Zhengzhou, Zhuhai
- Életkor
- 18 év and over
- People
- 170
- Run by
- 3D Medicines (Sichuan) Co., Ltd.
See details and how to joinNCT05024214 - 1/2. fázisTaking peopleAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 29
- Run by
- Tongji Hospital
See details and how to joinNCT07392541 - No phaseTaking peoplecfDNA Methylation for Liver Cancer Recurrence Detection
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 500
- Run by
- Wuhan Ammunition Life-tech Co., Ltd
See details and how to joinNCT07466602 - No phaseTaking peoplePrediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- Where
- Foshan, Guangzhou, Shaoguan
- Életkor
- 18 év to 75 év
- People
- 255
- Run by
- Zhujiang Hospital
See details and how to joinNCT06157060 - 1/2. fázisTaking peopleA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- Where
- Chengdu
- Életkor
- 18 év to 80 év
- People
- 33
- Run by
- West China Hospital
See details and how to joinNCT07482059 - No phaseNot yet taking people in KínaSafety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- Where
- Chengdu
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- Hong Wu
See details and how to joinNCT07480382 - 2. fázisTaking peopleA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Akeso
See details and how to joinNCT07052253 - 1. fázisTaking peoplePhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Lishui, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év to 65 év
- People
- 246 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07176650 - 2. fázisNot yet taking people in KínaA Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
- Where
- Nanjing
- Életkor
- 18 év to 70 év
- People
- 25
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07471165 - 2. fázisTaking peopleHepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 25
- Run by
- West China Hospital
See details and how to joinNCT06859684 - 1. fázisTaking peopleStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Where
- Beijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 330 worldwide
- Run by
- I-Mab Biopharma US Limited
See details and how to joinNCT04900818 - 1/2. fázisTaking peopleA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Where
- Beijing, Jinan
- Életkor
- 18 év to 75 év
- People
- 280
- Run by
- Akeso
See details and how to joinNCT06530251 - 1/2. fázisTaking peopleA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 135
- Run by
- Akeso
See details and how to joinNCT06938321 - No phaseTaking peopleSafety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Where
- Beijing, Chengdu, Xuzhou
- Életkor
- 18 év to 80 év
- People
- 200
- Run by
- West China Hospital
See details and how to joinNCT07295275 - No phaseTaking peopleImpact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 90
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07436845 - 2. fázisCsak meghívásosA Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- Where
- Hubei
- Életkor
- 18 év and over
- People
- 118
- Run by
- Abbisko Therapeutics Co, Ltd
See details and how to joinNCT05441475 - 1/2. fázisTaking peopleBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Where
- Beijing
- Életkor
- 8 év to 85 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT07410494 - 1/2. fázisTaking peopleEBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Where
- Beijing
- People
- 83
- Run by
- Essen Biotech
See details and how to joinNCT07410676 - 3. fázisTaking peopleAdjuvant TACE in HCC With High-risk Recurrence Factors
- Where
- Nanning
- Életkor
- 18 év to 70 év
- People
- 442
- Run by
- Guangxi Medical University
See details and how to joinNCT07417397 - No phaseTaking peopleA Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
- Where
- Wuhan
- People
- 103
- Run by
- Tongji Hospital
See details and how to joinNCT07326137 - 2. fázisTaking peoplePD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 62
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT05430698 - 2/3. fázisNot yet taking people in KínaA Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Where
- Nanjing, Shanghai
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
See details and how to joinNCT07392866 - 2. fázisTaking peopleCosiporfin Sodium for Injection Photodynamic Therapy
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 30
- Run by
- Shanghai Guangsheng Biopharmaceutical Co., Ltd
See details and how to joinNCT07398339